AcuityMD, FEMSelect Team Up on Pelvic Floor Disorder Tech

AcuityMD is partnering with FEMSelect to accelerate the identification and engagement of U.S. physicians treating pelvic floor disorders (PFDs), which affect at least one in five women.
 
In a 2022 study of more than 25,000 women, 32% suffered from a PFD. The current standard of care for one of the most common PFDs, pelvic organ prolapse (POP), involves a full hysterectomy or complex mesh surgery. FEMSelect’s U.S. Food and Drug Administration-cleared EnPlace, in contrast, offers a minimally invasive, meshless approach that can bring relief to the millions of women suffering from POP. The challenge for the Israel-based FEMSelect is to commercialize its innovation efficiently. After establishing a team of regional sales representatives, FEMSelect turned to AcuityMD’s commercial platform for faster, more accurate physician identification and planning.
 
“Our lean sales team has a lot of territory to cover in a short period of time, so we needed advanced technology to help us identify the microcosm of about 2,500 relevant specialists in the U.S.,” FEMSelect Co-CEO Debbie Garner said. “AcuityMD’s domain expertise, aggregated database of various sources, including private and public payers, and user-friendly interface made it an easy choice. Our sales team depends on the platform not just for physician identification but also for smart engagement strategies.”
 
“AcuityMD’s platform is continuously updated to add new data and rich functionality. It also saves our sales team a tremendous amount of time and gets very granular with its insights about specialists based on surgical experience and relevant patient populations for strategic call planning,” FEMSelect Market Development Manager Francesca Babore added.
 
In one month, FEMSelect has used the AcuityMD platform to identify more than 400 healthcare providers and 600 sites of care that could benefit from its technology. “As a startup trying to break into the U.S. market, we must be very smart and strategic about how we manage our resources. AcuityMD’s solution makes it faster to on-board sales representatives new to a region by delivering rich physician insights that could otherwise take many months to unearth and may not be as reliable. It’s truly instrumental to our commercialization efforts,” Garner stated.
 
With the pace of the medtech innovation accelerating, AcuityMD expanded its annual recurring revenue in 2022 by 317%, and customer growth by 253%, increasing its customer base to more than 80 medtech companies. AcuityMD’s platform translates large volumes of healthcare data, such as physician training backgrounds, procedural volumes, where surgeons operate, and peer networks, into intuitive workflows and recommendations that align with the medtech industry’s commercialization process. It has resulted in more than 25% sales growth for top active sales reps and over $4 billion in opportunity pipeline.
 
Founded in 2019, AcuityMD is a technology partner to the commercial medtech industry. With customers ranging from pre-commercial to enterprise, AcuityMD providing medtech firms with visibility to accelerate access to medical technology.